Overview

Aliskiren/Amlodipine/Hydrochlorothiazide (HCTZ) Versus Aliskiren/Amlodipine in US Minority Patients With Stage II Systolic Hypertension

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

The purpose of the study is to compare the combination of aliskiren, amlodipine and Hydrochlorothiazide (HCTZ) versus the combination of aliskiren and amlodipine as therapy in minority Stage 2 hypertensive patients.

Phase:

Phase 4

Details

Lead Sponsor:

Novartis

Treatments:

Amlodipine
Hydrochlorothiazide